
Opinion|Videos|January 15, 2025
Novel Nonstatin LLTs for Lowering LDL-C and CVD Risk
Key Takeaways
- Pediatric lipid screening is vital for early dyslipidemia detection, reducing future cardiovascular disease risk.
- Guidelines suggest universal screening at ages 9-11 and 17-21, with selective screening for at-risk children.
Panelists discuss how newer nonstatin therapies, such as PCSK9 inhibitors (inclisiran, alirocumab, evolocumab) and bempedoic acid, offer additional options for LDL-C reduction and cardiovascular risk management.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What are some of the newer, nonstatin LLTs that are approved for lowering LDL-Cand reducing CVD risk (eg, inclisiran, alirocumab, evolocumab, bempedoic acid)?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
OMA 2026 Recap: Pediatrics, Retention, and Lifestyle Changes in Obesity
2
A Real-World Case: Initiating Ritlecitinib After Years of Untreated Disease
3
Choosing Among Approved JAK Inhibitors: Baricitinib, Ritlecitinib, and Deuruxolitinib
4
CX11 Shows Weight Loss in Phase 2 Obesity Trial, Corxel Reports
5





































































